Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

CONCLUSIONS: The RAD51 test identifies tumors with functional HRD and is highly concordant with tBRCA mutation and genomic HRD. RAD51 independently predicts clinical benefit from adding Cb to NACT in TNBC. Our results support further development to incorporate RAD51 testing in clinical decision-making.PMID:34520831 | DOI:10.1016/j.annonc.2021.09.003

Source: Ann Oncol - September 14, 2021 Category: Cancer & Oncology Authors: A Llop-Guevara S Loibl G Villacampa V Vladimirova A Schneeweiss T Karn D-M Zahm A Herencia-Ropero P Jank M van Mackelenbergh P A Fasching F Marm é E Stickeler C Schem R Dienstmann S Florian V Nekljudova J Balma ña E Hahnen C Denkert V Serra Source Type: research